


EPSA Career Week

Maarten Van Baelen, Executive Director PPTA

7 April 2023



The Plasma Protein Therapeutics Association (PPTA) is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 1,000 human plasma collection centers in North America and Europe, as well as the manufacturers of lifesaving plasma protein therapies. Our members produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.

PPTA Global Strategic Pillars

PPTA mission:

“As a trusted partner to health systems, PPTA drives broad and reliable access to high-quality plasma protein therapies, with a focus on the well-being of patients and plasma donors.”



Pillar 1: Access to therapies: Advocate for patient access to plasma-derived medicines.



Pillar 2: Plasma availability - Responsibly improve the reliable availability of plasma.



Pillar 3: Awareness - Advance the understanding of the plasma ecosystem.


Plasma is a key blood component

BLOOD IS

55%
PLASMA

44%
RED BLOOD CELLS

1%
WHITE BLOOD CELLS
& PLATELETS



About Plasma & Plasma Therapies



Some 300,000 European patients rely on plasma-derived medicines every day to treat a range of critical medical conditions.

Without stable access to these treatments, many will not survive or will have a severely reduced quality of life.

What conditions do plasma-derived medicines treat?

PLASMA PROTEINS AND THE DISEASES THEY TREAT



- **Albumin (25 grams*)**
Shock, Burns, Trauma, Liver conditions, Cardiopulmonary Bypass Surgery
- **IVIG (Intravenous Immunoglobulin) (4 grams*)**
Primary Immunodeficiencies, Secondary Antibody Deficiencies, Immune-mediated Neurological Diseases; Primary Thrombocytopenic Purpura; Other Autoimmune Diseases
- **Alpha-I Antitrypsin (.15 to .30 grams*)**
Alpha-I Antitrypsin Deficiency (Genetic COPD)
- **Coagulation Factors (Factor VIII: 300 to 450 IUs, Factor IX: 180 to 200 IUs*)**
Hemophilia A & B, von Willebrand Disease, other Bleeding Disorders

** Plasma Protein Yields per Liter of Plasma*

The EU's growing patient population for plasma for medicines

PER PATIENT PER YEAR:

MORE THAN
1200:  Plasma donations to treat
ONE PATIENT for HEMOPHILIA.

MORE THAN
900:  Plasma donations to treat
ONE ALPHA-1 PATIENT.

MORE THAN
130:  Plasma donations to treat
ONE PATIENT with a
PRIMARY IMMUNE DEFICIENCY.

- **More precise medical diagnostics** open plasma-derived medicines to more people.
- **More clinical evidence** of the benefits of plasma-derived therapies.
- **Patients are living longer.**

Plasma key facts

Fact



Plasma cannot be made in a laboratory.

Plasma-derived medicines can only be made using human plasma that is generously given by donors.



Pharmaceutical medicines

are made from synthetic or chemical ingredients.

Two ways to donate plasma

Most efficient


	Extraction	Donation	Frequency	Duration	Volume
SOURCE PLASMA	<p>Donor Center</p> <p>Blood</p> <p>Red cells</p> <p>Plasma <i>direct plasma donation</i></p> <p>Used for making plasma-derived medicines</p>	<p>Plasma <i>plasmapheresis</i></p>	<p>1 x weekly</p>	<p>90 min</p>	<p>~820ml</p>
RECOVERED PLASMA	<p>Donor Center → Processing Center</p> <p>Blood</p> <p>Plasma <i>For hospital use (transfusion) + making plasma-derived medicines</i></p> <p>Red cells <i>Hospital use</i></p>	<p>Blood <i>blood donation</i></p>	<p>4-6 x yearly</p>	<p>30 min</p>	<p>~250ml</p>

The EU's plasma donation shortfall

Today, Europe has a shortfall of about **40%** of plasma needed to produce plasma-derived medicines.

(Source: Marketing Research Bureau, 2020)

#EUneedsmoreplasma




About me



2007: Mpharm, KU Leuven

2016: MBA – Solvay Business School, Brussels - Ecole des Ponts Business School, Paris



Toward better access to plasma-derived medicines in Europe

Better for patients

Better for health

Better for society

euneedsmoreplasma.com

